Effect of short-term rosiglitazone therapy in peritoneal dialysis patients

Perit Dial Int. 2009 Jan-Feb;29(1):108-11.

Authors

Simon van Hooland¹, Olivier Boey, Patricia Van der Niepen, Christiane Van den Branden, Dierik Verbeelen

Affiliation

¹ Department of Nephrology, Universitair Ziekenhuis Brussel, Brussels, Belgium. [email protected]

PMID: 19164260

No abstract available

Publication types

Comparative Study

MeSH terms

Administration, Oral
Blood Glucose / drug effects
Blood Glucose / metabolism
Diabetes Mellitus, Type 2 / blood
Diabetes Mellitus, Type 2 / complications
Diabetes Mellitus, Type 2 / drug therapy*
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Follow-Up Studies
Humans
Hypoglycemic Agents / administration & dosage
Hypoglycemic Agents / therapeutic use*
Insulin Resistance
Kidney Failure, Chronic / complications
Kidney Failure, Chronic / therapy*
Male
Middle Aged
PPAR gamma / agonists
Peritoneal Dialysis / methods*
Pilot Projects
Prospective Studies
Rosiglitazone
Thiazolidinediones / administration & dosage
Thiazolidinediones / therapeutic use*
Time Factors
Treatment Outcome

Substances

Blood Glucose
Hypoglycemic Agents
PPAR gamma
Thiazolidinediones
Rosiglitazone